What this is
Working notes on bland transarterial embolisation, why blocking a vessel kills a tumour, and what makes one embolic agent different from the next. Written from the vantage of someone in the room assisting, trying to make sense of what gets handed across the trolley and why.
Why This Procedure Works at All
Most solid tumours survive by building their own blood supply, recruiting and rerouting nearby arteries to feed themselves. Transarterial embolisation (TAE) works by finding that supply and blocking it.
The doctor threads a thin tube (a catheter) up through an artery (usually entered at the groin or wrist) and steers it toward the vessel feeding the tumour under real-time X-ray guidance. That’s what’s showing on the screens throughout the case: the operator mapping the plumbing, working out what feeds where, and finding the right spot to deploy the blocking agent.
“Bland” just means no drugs are added. The procedure works on ischaemia alone. Cut off the blood, cut off the oxygen, and the tissue dies.
The whole logic, in one line
Block the artery feeding the tumour, and the tumour dies while the rest of the organ carries on.
Does It Actually Work? The TAE vs TACE Question
You’ll also see TACE (transarterial chemoembolisation) on the theatre list. It’s essentially the same procedure, but with chemotherapy drugs added. For a long time the assumption was that the chemo made a meaningful difference.
The data doesn’t support that assumption.
Multiple large studies have found no meaningful difference in survival between the two approaches for liver cancer:
| Treatment | Average Survival |
|---|---|
| TACE (standard) | 18.1 months |
| TACE (drug-eluting beads) | 20.6 months |
| Bland TAE (no drugs) | 20.8 months |
The leading explanation is that liver cancer is naturally resistant to chemotherapy. The blockage itself is doing the heavy lifting. The drugs may simply be along for the ride.
This is why you’ll sometimes see the team choose plain TAE over TACE, particularly for patients whose livers are already under strain. Removing the chemotherapy from the equation removes one more thing the liver has to deal with.
What Makes the Agents Different
The interesting thing about embolisation agents is that they don’t all work in the same part of the vessel tree. Some block large vessels close to the surface. Some travel deep into tiny capillaries right at the tumour’s doorstep. Some dissolve over time, others are permanent. And some you can reposition before committing, while others are one-shot decisions.
That’s really the framework the team is working from when they choose.
Spongostan: the one that dissolves
Spongostan is an absorbable gelatin sponge, the only agent in common use that the body actually breaks down and resorbs. Once injected, it acts as a physical plug, but over two to six weeks the body treats it like a foreign object, clears it away, and the vessel gradually reopens.
In the scrub nurse role, you’ll often be asked to prepare it before it goes across. It can be cut into small torpedo-shaped pieces for larger vessels, or mixed with contrast and saline into a slurry when smaller vessels are targeted. The contrast makes it visible under fluoroscopy, which is why you’ll see it mixed rather than used dry.
Temporary in intention, not always in practice
Recanalisation (the vessel reopening) isn’t guaranteed. In some patients the vessel stays closed because scar tissue forms as the sponge dissolves. So while the team chooses Spongostan because they want temporary blockage, they can’t always predict the outcome.
The situations where temporary matters: postpartum haemorrhage (where preserving fertility is the goal), cases where the team expects to come back and repeat the procedure, or acute bleeding where short-term control is all that’s needed right now.
PVA particles: the workhorse
PVA (polyvinyl alcohol) particles are tiny, irregular fragments. Think rough-edged bits of plastic foam measured in fractions of a millimetre. They come suspended in saline in a vial. Once injected, they travel down the artery and lodge together, building up a permanent blockage.
The important thing to understand about non-spherical PVA is that they clump. Because of their irregular shape, they aggregate, both inside the vessel and sometimes inside the catheter itself. That clumping means they tend to block the vessel further back from the tumour than you’d expect based on their size alone.
For bigger vessels where blockage closer to the source is fine, that’s not a problem. Where it matters is when the team needs to reach small, deep feeding vessels right at the tumour. PVA often won’t get there reliably.
Worth knowing for anyone handling the syringes
If the catheter clogs with particles mid-procedure and gets flushed, the particles can end up somewhere unintended. The team will inject slowly and deliberately. If you’re drawing up or managing the syringes, slow and careful matters more than fast.
Cook PVA and Contour PVA (Boston Scientific) are the two you’ll see most often. They behave the same way, the choice between them is usually about what’s on contract or what the team is used to.
Contour SE microspheres: precise and deep
These look similar to PVA in the vial, but behave quite differently. They’re perfectly spherical and manufactured to tight size tolerances. Every particle in the vial is essentially the same diameter.
That uniformity is what makes them interesting. Because they’re round and consistent, they don’t clump. They travel further down the vessel tree before stopping, and when they do stop they pack together evenly. The blockage ends up deeper and more complete, right at the tumour’s feeding vessels rather than in a larger vessel further upstream.
You may be asked to draw these up into a syringe and mix them with contrast. They settle quickly, so a gentle roll of the syringe before handing it across keeps them evenly distributed. Small thing, but worth knowing.
The trade-off is cost. They’re more expensive than non-spherical PVA. When you see the team reach for them, it’s usually because thorough, deep devascularisation (cutting off the blood supply right at the tumour) is the priority: liver tumours, uterine fibroids, hypervascular metastases.
Cook coils: fast, permanent, no going back
Coils are a completely different category. Where particles work by accumulating into a blockage, a coil is a single structural device, a thin platinum wire wound into a tight spiral, often threaded with small fibres that help blood clot around it. They come individually packaged, labelled by diameter and length.
The doctor pushes the coil through the catheter directly into position. Once it’s seated in the vessel, blood clots around it and the vessel closes permanently. The mechanism is partly mechanical (the coil physically fills the space) and partly biological (the fibres trigger clotting).
What you’ll notice in the room: coil selection is a deliberate process. The operator will check the vessel diameter on fluoroscopy and call for a specific size. Handing the wrong diameter matters. Too small and it migrates, too large and it won’t deploy properly.
Why speed matters here
In a patient who’s actively losing blood faster than the body can compensate, the team often goes straight to coils. They’re quick to deploy, reliable, and stop flow immediately. You won’t see a lot of deliberation in that scenario. The priority is the bleed, and coils are the fastest route to stopping it.
The one thing everyone in the room understands: once a pushable coil exits the catheter tip, it’s there. It cannot be retrieved or repositioned. The team commits to the placement before deploying. You’ll often hear a pause and a confirmation before the coil goes in.
Concerto coils: the same job, more control
Concerto coils (Medtronic) do essentially the same thing as Cook’s pushable coils, with one meaningful difference: the operator controls the moment of release.
Using a small handheld detachment mechanism, the coil can be advanced into position and, if the placement isn’t right, pulled back and repositioned before it’s released. Only when the team is satisfied does it detach permanently.
You’ll notice these cases feel slightly slower and more deliberate. More back-and-forth on the fluoroscopy screens, more conversation between the operator and the radiographer before anything gets released. That’s the point. The detachability is buying precision.
They cost significantly more than pushable coils, so they’re not the default. The team reaches for them when the anatomy is complex or the stakes of a misplaced coil are high: aneurysms (abnormal bulges in a vessel wall), arteriovenous fistulas (abnormal connections between arteries and veins), or cases where getting it slightly wrong would mean blocking the wrong vessel entirely.
Layering the Blockage
In areas like the liver or pelvis, tumours often have access to multiple backup blood vessels. Block one feeder and the tumour can recruit another route. This is where you’ll sometimes see the team use more than one agent in the same case.
The approach (sometimes called the sandwich technique) is to push particles deep first, into the small tumour feeders, and then seal the larger upstream vessel with coils. Particles close the exits, coils close the main gate.
If you notice the team switch agents partway through, or the case running longer than expected with two different products going across the trolley, this is often what’s happening.
Quick Reference
| Agent | Where it blocks | Permanent? | Typically used for |
|---|---|---|---|
| Spongostan | Mid-vessel | No (2–6 wks) | Postpartum haemorrhage, repeat procedures, acute bleeding |
| Cook / Contour PVA | Closer to source (clumps) | Yes | Larger vessel blockage, cost-sensitive cases |
| Contour SE microspheres | Distal, deep | Yes | Thorough tumour devascularisation (liver, fibroids) |
| Cook coils (pushable) | Larger vessel, closer to source | Yes | Acute bleeding, vessel sacrifice, sandwich technique |
| Concerto coils (detachable) | Larger vessel, closer to source | Yes | Aneurysms, AVFs, complex anatomy requiring precision |
Related
- Liver Tumour Embolisation, where TAE sits among the four liver-embolisation modalities
- Acetabulum Tumour Embolisation, same agents, different territory and a particular reason coils go in first
- Transarterial Chemoembolisation (TACE) (upcoming note)
- Uterine Fibroid Embolisation (upcoming note)
- Interventional Radiology — Procedures Overview (upcoming note)
Sources
- Outcomes of TAE vs TACE for HCC: Systematic Review and Meta-Analysis — MDPI Cancers 2023
- Survival Analysis of 230 Patients with Unresectable HCC Treated with Bland TAE — PLOS ONE 2020
- Transarterial Chemoembolisation and Bland Embolisation for HCC — PMC Review
- Embolic Agents: Particles — PMC NIH 2023
- Embolic Agents: Coils — PMC NIH 2022
- An Overview of Embolic Agents — PMC NIH
- The Common but Complicated Tool: Review of Embolic Materials — PMC 2021
- Gelatin Sponge: Guidelines on Use in Embolotherapy — PubMed
- Characterization of Calibrated Gelatin Sponge Particles in Rabbit Renal Model — PubMed
- A Case-Based Approach to Embolisation Agents — AJR
- Clinical Versatility of Concerto Detachable Coils — Endovascular Today 2014
- Concerto Detachable Coil System — Medtronic
- PURE Trial: Non-Spherical PVA vs Calibrated Microspheres — CVIR 2022
- Embolic Agents in IR: Classification and Selection Criteria — INVAMED
Last updated May 18, 2026.